SAN FRANCISCO – (BUSINESS WIRE) – Virta Health, the leading provider of type 2 diabetes reversals, today announced the release of new, peer-reviewed research on nutrients. In this publication, Virta reports world-class results in diabetes prevention, with only 3% of study participants transitioning to type 2 diabetes (T2D) and more than half achieving a reversal of prediabetes in the first two years. In addition, the study found strong retention, with 75% of patients being withheld after two years.
Notably, these numbers surpass the results of the National Institutes of Health Diabetes Prevention Program (NIH DPP) and its real-world translation, the National Diabetes Prevention Program (NDPP), which is considered the gold standard for treating prediabetes.
An estimated 88 million Americans, or about a third of the population, have prediabetes, according to the CDC. Of these patients, 30% will transition to T2D within five years. Today’s release shows that this high rate of progression is not inevitable.
Key findings that demonstrate the success of Virta’s approach include:
-
Progression to type 2 diabetes: Over two years, only 3% of Virta patients developed type 2 diabetes. In the NIH-DPP study, approximately 8% of lifestyle intervention, 15% of metformin-treated patients, and 22% of controls achieved T2D.
-
Prediabetes Reversal: During the biennium, 52% of Virta patients achieved prediabetes reversal by lowering HbA1c below the drug-free prediabetes diagnostic threshold. Myocardial infarction, stroke, and death.
-
Weight Loss: Virta patients experienced an average weight loss of 11.3% after two years, more than doubling the NDPP’s 5% target for prediabetes.
-
Retention: The retention for one and two years was 80% and 75%, respectively. For the context, the one-year NDPP retention was 13.2%.
“The overwhelming number of patients who either achieve normal blood sugar or avoid type 2 diabetes progression further demonstrates the effectiveness of Virta’s reversal therapy in a variety of metabolic disorders,” said Dr. Robert Ratner, Chief Medical Officer at Virta Health. “Dietary changes can be difficult to sustain, but the remarkable adherence and retention shows both the acceptability and durability of the Virta approach to both the prevention and management of diabetes.”
Today’s news supports Virta’s recent addition to the clinical offering. Virta now offers T2D treatment, prediabetes reversal, and obesity treatment to members of its corporate, health plan, and government customers. The company also offers diabetes management with personalized guidance and an option to seamlessly transition to Virta T2D reversal treatment when patients are ready.
“Before I came to Virta five years ago, I had tried everything to get my prediabetes under control, but my numbers continued to creep up,” said Cathy McKinnis, a clinical trial participant. “Thanks to Virta, I reversed my prediabetes and lost 50 pounds. This treatment really works and Virta offers the support to make it permanent. ”
For more information on Virta’s research and treatment to reverse type 2 diabetes and prediabetes, please visit www.virtahealth.com.
About Virta Health:
Virta Health helps people reverse type 2 diabetes and other chronic conditions. Current approaches control the progression of the disease through increased use of drugs and infrequent visits to the doctor. Virta reverses type 2 diabetes through innovations in technology, nutritional science, and ongoing remote care from doctors and behavioral experts. In clinical trials, 94% of patients reduce or eliminate insulin use and weight loss exceeds FDA benchmarks by 150%. Virta works with the largest healthcare plans, employers and government organizations and puts 100% of its fees at risk based on clinical and financial results. To learn more about how Virta is changing lives by reversing type 2 diabetes and other chronic diseases, visit www.virtahealth.com or follow us on Twitter @virtahealth.
